Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1126 clinical trials
IPG7236 in Patients With Advanced Solid Tumors

This is a Phase 1, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients with Advanced Solid Tumors. The study will include a dose escalation phase (Part 1) and a dose …

  • 0 views
  • 03 Dec, 2021
  • 1 location
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

measurable disease
progressive disease
advanced solid tumor
sarcoma
breast cancer
  • 0 views
  • 05 Aug, 2020
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Eligibility Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options.

pediatric
platelet count
blood tests
gilbert's syndrome
renal function test
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of SGN-B6A in Advanced Solid Tumors

It will also study whether SGN-B6A works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is …

gastric cancer
ovarian cancer
squamous cell carcinoma
squamous cell carcinoma of the head and neck
ovarian ca
  • 0 views
  • 05 Aug, 2020
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

screening procedures
fulvestrant
measurable disease
HER2
hormone therapy
  • 0 views
  • 16 Feb, 2024
  • 5 locations
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

measurable disease
HER2
epidermal growth factor receptor
breast cancer
advanced malignant solid tumor
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Phase 1 Multi-Center Safety Dose Escalation Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors

The safety, tolerability, and PK of INV-1120 will be assessed in adult patients with advanced solid tumors.

measurable disease
ct scan
beta human chorionic gonadotropin
serum pregnancy test
renal function test
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Giving avelumab together with M6620 may help to control DDR deficient metastatic or unresectable solid tumors.

tubal occlusion
progestin
hormonal contraception
BRCA1
measurable disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

direct bilirubin
platelet count
gilbert's syndrome
gene fusion
ffpe
  • 0 views
  • 16 Feb, 2024
  • 1 location
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.

solid tumour
treatment regimen
solid neoplasm
  • 0 views
  • 16 Feb, 2024
  • 1 location